A medical worker prepares a dose of the AstraZeneca/Oxford University jab
Credit: Baz Ratner/Reuters
The AstraZeneca coronavirus vaccine provides a "significant benefit" in avoiding hospital admission across all age groups, the European Medicines Agency (EMA) has said.
Overall, the benefits of the jab continue to outweigh the risks of rare blood clots, and benefits increase in older age groups and in areas with higher levels of coronavirus infection, the regulator said.
The EMA said its human medicines committee (CHMP) had analysed available data on the vaccine to put the risk of rare blood clots into context of benefits for different age groups and different rates of infection.